Daniel Adler, CEO & Co-Founder, BioT
Ph.D. President, Vascular Sciences
This webinar highlights the growing role that device manufactures can play in the reimbursement process as the industry moves towards a connected care model with the IoMT. Accurate measurement of device usage is essential for RPM and RTM CPT billing. Managing connected devices, manufacturers have access to key information beyond that collected by Patient Monitoring providers.
Join us to learn how the effective measurement of reimbursements relies on input from device manufacturers and what steps are needed to bring medical devices in line with this new reality.
The webinar will cover:
- Why the device manufacturers must be part of the reimbursement eco-system
- How to integrate reimbursement strategy into product development
- How to enable a smooth reimbursement process for your customers
- How to automate and efficiently manage reimbursement of RPM and RTM CPT Codes
- What are the key functionalities of a reimbursement module?
This webinar is aimed atdecision makers and product leaders in the medical device industry, exploring the benefits of connecting their existing solution to facilitate remote care and billing for remote services.
Daniel Adler, CEO & Co-Founder, BioT
Daniel is the CEO & Co-Founder of BioT and has extensive experience in IT, Internet and telecom. Previously, he was leading business activities as part of the management team in leading Israeli high-tech companies in the areas of high-speed communication, data collection and analysis.
BioT specializes in providing a no-code medical grade and fully secured cloud-based, connected care platform, which allows to dramatically shorten the time it takes to transform medical devices into a fully compliant and cyber secured connected care solution - from years to a few days.
Michael Drues, Ph.D. President, Vascular Sciences
Dr. Michael Drues is the President of Vascular Sciences, offering specialized consulting services to enhance the overall value of medical device, biotechnology and pharmaceutical products from prototype design through the implementation of effective product development and regulatory strategies. He works on a regular basis for the U.S. Food and Drug Administration (FDA), Health Canada, the US and European Patent Offices, the Centers for Medicare and Medicaid Services (CMS) and other regulatory and governmental agencies around the world.
Dr. Drues is an Adjunct Professor in both Cornell University Graduate Dept. of BioMedical Engineering and The George Washington University School of Medicine and Health Sciences, lecturing in regulatory science, medicine, biomedical engineering and biotechnology.